Form S-8 Sarepta Therapeutics,
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
BMO Capital Reiterates Market Perform Rating on Sarepta Therapeutics (SRPT) Following Mgmt. Meeting
August 7, 2025 11:05 AM EDTBMO Capital analyst Kostas Biliouris reiterated a Market Perform rating and $50.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).
The analyst comments "We hosted an investor call with management post 2Q earnings and takeaways include: (1) Management resumed Elevidys infusions following the pause (first infusion on 8/5)... More
